6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C β-lactamases I

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 7, 1999, Pages 991-996

  Bitha, Panayota ^a   Li, Zhong ^a   Francisco, Gerardo D ^a   Rasmussen, Beth A ^a   Lin, Yang I ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINOMETHYL 3 TETRAHYDROFURANYLTHIO) 6 (1 HYDROXYETHYL) 1BETA METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; 6BETA HYDROXYMETHYLSULBACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; OCA 983; PENICILLINASE; PIPERACILLIN; SULBACTAM; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY;

ANIMALS; BETA-LACTAMASES; ENZYME INHIBITORS; MICE; SULFONES;

OXALIS TUBEROSA;

EID: 0033526062     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00106-7     Document Type: Article

References (23)

1. 1. (a) Coleman, K. Expert Opin. Invest. Drugs 1995, 4, 693.
2. (b) Sutherland, R. Infection 1995, 23(4), 191.
3. 2. (a) Nordmann, P.; Naas, T. Current Opin. In Infectious Diseases 1997, 10, 435.
4. (b) Piddock, L. J. V.; Walter, R. N.; Jin, Y.-F.; Turner, H. L.; Gascoyne-Binzi, D. M.; Hawkey, P. M. J. Antimicrobial Chemotherapy 1997, 39, 177.
5. (c) Moosdeen, F. Clinical Infectious Diseases 1997, 24, 487.
6. (d) Sanders, W. E., Jr.; Sanders, C. C. Clin. Microbiol. Rev. 1997, 10, 220.
7. 3. (a) Ambler, R. P. Philosophical Transactions of the Royal Society, London 1980, 289, 321.
8. (b) Bush, K.; Jacoby, G. A.; Medeiros, A. A. Antimicrob. Agents Chemother. 1995, 39, 1211.
9. 4. (a) Lin, Y.-I; Bitha, P.; Sakya, S. M.; Strohmeyer, T. W.; Li, Z.; Lee, V. J.; Lang, S. A., Jr.; Yang, Y.; Bhachech, N.; Weiss, W. J.; Petersen, P. J.; Jacobus, N. V.; Bush, K.; Testa, R. T.; Tally, F. P. Bioorg. Med. Chem. Lett. 1997, 7, 1665.
10. (b) Lin, Y.-I; Bitha, P.; Sakya, S. M.; Li, Z.; Strohmeyer, T. W.; Lang, S. A., Jr.; Yang, Y.; Bhachech, N.; Weiss, W. J.; Petersen, P. J.; Jacobus, N. V.; Bush, K.; Testa, R. T. Bioorg. Med. Chem. Lett. 1997, 7, 1671.
11. 5. 6-Hydroxyethyl-and 6-hydroxymethylsulbactams are genetically covered by Pfizer's patents; for example, DE3039505 and US4287181 invented by M. S. Kellogg.
12. 6. Micetich, R. G.; Maiti, S. N.; Spevak, P.; Tanaka, M.; Yamazaki, T.; Ogawa, K. Synthesis 1986, 292.
13. 7. Brown, B. B.; Volkmann, R. A. Tetrahedron Lett. 1986, 27, 1545.
14. 8. Richter, H. G. F.; Angehrn, P.; Hubschwerlen, C.; Kania, M.; Page, M. G. P.; Specklin, J.-L.; Winkler, F. K. J. Med. Chem. 1996, 39, 3712.
15. 9. Sacripante, G.; Just, G. J. Org. Chem. 1987, 52, 3659.
16. 10. Schlosser, M.; Jenny, T.; Guggisberg, Y. Synlett. 1990, 11, 704.
17. 11. Miyashita, K.; Massova, I.; Mobashery, S. Bioorg. Med. Chem. Lett. 1996, 6, 319.
18. 12. Karplus, M. J. Chem. Phys. 1959, 30, 11.
19. 2O are summarized as follows: δ: 4.94 (1H, d; J = 4.5 Hz), 4.2 (1H, s), 4.2-4.14 (1H, m), 4.15-3.92 (2H, m), 1.46 (3H, s), 1.34 (3H, s).
20. 14. Miyashita, K.; Massova, I.; Taibi, P.; Mobashery, S. J. Am. Chem. Soc. 1995, 117, 11055.
21. 15. Imtiaz, U.; Billings, E. M.; Knox, J. R.; Mobashery, S. Biochemistry 1994, 33, 5728.
22. 16. Bulychev, A.; Massova, I.; Miyashita, K.; Mobashery, S. J. Am. Chem. Soc. 1997, 119, 7619.
23. 17. Molecular modelling studies using MacroModel v6.0 showed that good binding ligands fit well in the enzyme active site and remained there during the molecular dynamics simulation. Details of the molecular modelling studies will be published elsewhere.